 |
|
|
|
|
|
NexACT® - Multi-Route Drug Delivery Technology
NexACT®, a clinically validated multi-route drug delivery technology, utilizes patented and highly effective novel excipients or "penetration enhancers" to dramatically improve absorption and bioavailability of drugs. Varying the concentration of the enhancer allows for local or systemic delivery of drug, as desired.
Our most advanced enhancer NexACT-88 is currently in use in formulations containing various actives, from small molecule to proteins, antibodies and RNAi therapeutics, and has been clinically evaluated in close to 5,000 subjects and over 150 pharm/tox studies.
The NexACT® technology utilizes biodegradable excipients, that when incorporated into drug formulations, will help overcome the body's natural barrier properties and enable rapid penetration of high concentrations of active drug directly through the skin and major biological membranes, resulting in more effective therapies. Future applications of the NexACT® technology will be driven primarily by in-house development strategy and through out-licensing to pharmaceutical and biotechnology companies worldwide.
NexMed has incorporated the NexACT® technology in a number of therapies indicated for a wide range of indications and across different classes of drugs.
Chemical structure of DDAIP HCl (Dodecyl 2-(N, N dimethylamino)-propionate)
NexACT® Multi-Route drug delivery technology facilitates compounds crossing the lipid bilayer and yet biodegrades in vivo to natural amino acids and natural fatty acids.
This technology is useful for:
- Penetrating, proprietary, topical & transdermal formulations
- Improving oral bioavailability of poorly soluble, poorly permeating compounds
(BCS class 2-4)
- Delivering siRNA therapeutics into the cells; in vivo validated
- Development of more effective, penetrating cosmeceutic formulations
- Preservative
The safety and permeation properties of this proprietary excipient DDAIP HCl from Apricus Bio/NexMed USA was demonstrated in the Vitaros® product which was approved November 2010 by Health Canada, and filed in the European Union in April 2011.
Due to the robust toxicological and pharmacological safety package of this “Functional Non-active Excipient”, and together with the clinical results from more than 5,000 treated subjects, we are ready today for commercial usage and licensing.
Finally, the DDAIP HCl compound has robust patent protection, with approximately 134 composition of matter patents, formulation patents, and route of delivery patents.
For more information, contact [email protected]
|
| |
|
| |
|
|
|
